ProfileGDS5678 / 1424053_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 93% 93% 93% 93% 93% 93% 94% 93% 93% 93% 94% 93% 93% 93% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.9135293
GSM967853U87-EV human glioblastoma xenograft - Control 27.8891893
GSM967854U87-EV human glioblastoma xenograft - Control 37.8957293
GSM967855U87-EV human glioblastoma xenograft - Control 48.1452593
GSM967856U87-EV human glioblastoma xenograft - Control 57.9866593
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.6806193
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.9099494
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.8202893
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.9016993
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.9216293
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.0852594
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.9854293
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.9215593
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.8707693